Hypertension Clinical Trial
To determine whether a population with isolated systolic hypertension (ISH) had a higher prevalence of carotid disease than a normotensive population matched for age and sex, and to determine specific risk factors for carotid disease.
BACKGROUND:
The Systolic Hypertension in the Elderly Program was a multicenter controlled clinical trial
supported by the NHLBI to study the cardiovascular and psychological effects of isolated
systolic hypertension in the elderly and to determine the efficacy and evaluate possible
adverse effects of drug treatment for this condition. A total of 4,736 patients were
followed until 1991. Elderly individuals with isolated systolic hypertension are clearly at
increased risk of both heart attack and stroke. This group has been shown in pilot studies
to also have high prevalence of carotid disease and lower extremity arterial disease.
Selected risk factors such as older age, male sex, and smoking were found to be related to
an increased prevalence of disease. This study allowed validation of these initial
observations.
DESIGN NARRATIVE:
This study was ancillary to the Systolic Hypertension in the Elderly Program (SHEP) clinical
trial. Participants of the SHEP at the University of Pittsburgh were used for the
hypertensive population. Patients screened for SHEP but rejected because of normal blood
pressure were used for the controls. Carotid disease was assessed by duplex scanning, a
noninvasive technique that combined real time B-mode ultrasound with Doppler ultrasound,
producing a system capable of both vessel imaging and analysis of blood flow
characteristics. Other evaluations included ankle systolic blood pressure measurements to
detect lower extremity arterial disease, complete history and physical examination,
electrocardiogram, blood lipoprotein levels, fasting insulin and glucose levels, hemoglobin,
and hematocrit. Thus, the effects of various risk factors on the development of carotid
atherosclerosis were evaluated as well as the relationship between carotid atherosclerosis
and peripheral arterial disease of the lower extremities. The first six months of the study
consisted of preparation and reproducibility testing of duplex scan measurements. During the
following three years, duplex scans and other evaluations were completed on all 400
participants. During the final half of the fourth year, the first 100 duplex scans of
hypertensive participants were repeated to determine whether it was possible to measure
disease progression using this methodology. The study began in FY 1988 under R29HL39871 and
continued in FY 1993 under R01HL50439.
The study was renewed in 1998 for an additional three years through June, 2003. The study
continued to investigate the prevalence and prognostic value of subclinical atherosclerosis
in the Pittsburgh SHEP cohort and a cohort of normotensive controls. Annual telephone
follow-up of the remaining 178 SHEP participants and 168 controls continued. A final clinic
visit included measures of coronary and aortic calcification using electron beam computed
tomography (CT), pulse wave velocity as a measure of aortic stiffening and cognitive
function testing. For the Pittsburgh SHEP cohort, the antihypertensive treatment effect was
striking with event rates for the active and placebo groups continuing to diverge beyond the
end of SHEP. Successful demonstration of a treatment effect on coronary calcium scores would
be the first randomized data showing an antihypertensive effect directly in the coronary
arteries. Risk factors for coronary calcification were evaluated, producing data of a type
not yet available in the literature for older adults and not being collected in any other
ongoing studies of the elderly. The added measures of vascular stiffness supplemented the
extensive data on subclinical atherosclerosis already available for this cohort. The extent
to which these measures predicted cardiovascular events was evaluated.
The study completion date listed in this record was obtained from the "End Date" entered in
the Protocol Registration and Results System (PRS) record.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |